Oncology drug pipeline

Cancer therapeutics across solid tumours and haematologic malignancies. Largest single therapeutic area by R&D spend and approval volume.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. Pfizer · 160 drugs
2. · 118 drugs
3. AstraZeneca · 111 drugs
4. Sun Yat-sen University · 90 drugs
5. Pfizer Inc. · 71 drugs
6. Merck Sharp & Dohme LLC · 54 drugs
7. Bristol-Myers Squibb · 47 drugs
8. GlaxoSmithKline · 47 drugs
9. Hoffmann-La Roche · 47 drugs
10. Amgen · 45 drugs

Key drug classes

• PD-1 inhibitor · 210
• PD-L1 inhibitor · 73
• Combination chemotherapy regimen · 49
• PI3K inhibitor · 46
• Monoclonal antibody · 45
• Alkylating agent · 42
• GnRH agonist · 39
• Platinum-based chemotherapy · 38
• Kinase Inhibitor [EPC] · 36
• Platinum-based chemotherapy agent · 35
• Tyrosine kinase inhibitor · 32
• CAR-T cell therapy · 30
• FGFR inhibitor · 29
• PD-1/PD-L1 inhibitor · 26
• Corticosteroid · 25

Major diseases in this area

• breast cancer
• non small cell lung cancer
• multiple myeloma
• colorectal cancer
• pancreatic cancer
• melanoma

Subscribe

Get oncology approvals + PDUFA dates in your RSS reader:

• Oncology RSS feed · Atom · JSON

Other therapeutic areas